Kidswell Bio Overview
- Founded
-
2001
- Status
-
Public
- Employees
-
38
- Stock Symbol
-
4584
- Investments
-
4
- Share Price
-
$1.64
- (As of Friday Closing)
Kidswell Bio General Information
Description
Kidswell Bio Corp is a biopharmaceutical company engaged in the discovery and development of drugs.
Contact Information
Website
www.kidswellbio.com
Formerly Known As
Gene Techno Science Co., Ltd., Gene Techno, Gene Techno Science Co, Gene Techno Sciences, Gene Techno Science
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Primary Industry
Biotechnology
Other Industries
Pharmaceuticals
Drug Discovery
Stock Exchange
TKS
Primary Office
- 3rd Floor, Kanayama Building
- 1-2-12, Shinkawa
- Tokyo, Chuo-ku
- Japan
+81 00-0000-0000
Kidswell Bio Stock Performance
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $1.64 | $1.62 | $1.35 - $2.65 | $52.1M | 32.1M | 117K | -$0.16 |
Kidswell Bio Financials Summary
|
In Thousands, USD |
TTM 31-Dec-2022 | FY 2022 31-Mar-2022 | FY 2021 31-Mar-2021 | FY 2020 31-Mar-2020 |
|---|---|---|---|---|
| EV | 65,267 | 113,670 | 126,657 | 122,502 |
| Revenue | 14,555 | 13,968 | 9,398 | 9,912 |
| EBITDA | (4,593) | (9,271) | (67,218) | |
| Net Income | (4,838) | (4,764) | (9,444) | (67,288) |
| Total Assets | 31,829 | 28,705 | 35,661 | 33,238 |
| Total Debt | 15,825 | 5,735 | 9,971 | 11,335 |
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
Kidswell Bio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Kidswell Bio Patents
Kidswell Bio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| JP-WO2019216438-A1 | Periodontal disease therapeutic agent containing culture supernatant of mesenchymal cells | Pending | 11-May-2018 | ||
| CA-3075867-A1 | Anti-ramp2 antibody | Inactive | 13-Sep-2017 | ||
| JP-WO2019054460-A1 | Anti-ramp2 antibody | Active | 13-Sep-2017 | 0 | |
| JP-2022169737-A | Anti-ramp2 antibody | Pending | 13-Sep-2017 | ||
| US-20200270579-A1 | Method for preparing dental pulp stem cells from cells derived from dental pulp tissue | Inactive | 03-Feb-2017 | C12N5/0664 |
Kidswell Bio Executive Team (5)
Kidswell Bio Board Members (1)
| Name | Representing | Role | Since |
|---|---|---|---|
| Masanari Kawaminami | Kidswell Bio | President & Board Member | 000 0000 |
Kidswell Bio Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
Kidswell Bio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
Kidswell Bio Investments & Acquisitions (4)
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| 000000000 | 11-Mar-2020 | 00000 0000 | 000.00 | Drug Discovery | |
| 00000000 0000 | 17-Jan-2019 | 0000000000 | Other Healthcare Services | ||
| 00000000 0000 | 30-Mar-2018 | 00000 0000 | Other Healthcare Services | ||
| OrthoReBirth | 27-Nov-2014 | Seed Round | 00.00 | Other Devices and Supplies | 00000000 |
Kidswell Bio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Biotechnology
Subindustry
Rank
Percentile
Kidswell Bio Exits (2)
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| 00000000 0000 0000 | 17-Jan-2019 | 000000000000000000 | Completed |
|
|
| Advanced Cell Technology and Engineering | 30-Mar-2018 | Later Stage VC | Completed |
|